Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
Gilead Sciences announced positive Phase 3 trial results for Livdelzi in treating primary biliary cholangitis. The drug demonstrated significant normalization of liver markers in patients who had an incomplete response to standard treatments.
Why it matters
This represents a potential advancement in treatment options for patients with chronic liver disease who have limited therapeutic alternatives.
News Releases Gileads-Livdelzi-Seladelpar-Delivers-Statistically-Significant-Composite-ALP-Normalization-in-Phase-3-IDEAL-Trial-in-Primary-Biliary-Cholangitis-PBC June 2, 2026 Gilead’s Livdelzi (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC) Back – IDEAL Evaluated Livdelzi in People Living with PBC with Elevated ALP Levels (1-1.67xULN) on or Intolerant to UDCA –
The article is a standard corporate press release regarding clinical trial data.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in